Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for Prime Medicine in a report issued on Monday, March 10th. Chardan Capital analyst G. Livshits anticipates ...

Stock analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Prime Medicine in a ...

Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox ...

Prime Medicine, Inc. (NASDAQ ... If you are looking for an AI stock that is more promising than PRME but that trades at less than 5 times its earnings, check out our report about the cheapest ...

In a report released on February 28, Eric Joseph from J.P. Morgan maintained a Buy rating on Prime Medicine, Inc. (PRME – Research Report), ...

Assess today's live Prime Medicine Inc (PRME) share price, performance and insights using our live NASDAQ: PRME stock exchange data. Analyse the historical data and Prime Medicine Inc share price ...

Prime Medicine, Inc. (NASDAQ ... If you are looking for an AI stock that is more promising than PRME but that trades at less than 5 times its earnings, check out our report about the cheapest ...

This data could potentially result in significant stock movement ... Begin your TipRanks Premium journey today. Prime Medicine, Inc. (PRME) Company Description: Prime Medicine Inc is a ...

Feb. 28, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies ...

Prime Medicine, Inc. (Nasdaq: PRME) today announced the pricing of an underwritten upsized public offering of 19,200,001 shares of its common stock at a public offering price of ...

GLUE Monte Rosa Therapeutics, Inc.